SunLink (SSY) shareholders adjourn merger vote; reconvene on Aug 4

Q: When will SunLink's reconvened special meeting take place?

4 Aug 2025 at 10:00 a.m. ET at Hyatt House Hotel, 3595 Cumberland Blvd., Atlanta.

Q: What were the vote totals for the adjournment proposal at SSY's special meeting?

For: 3,205,684 ; Against: 863,979 ; Abstentions: 911 ; no broker non-votes.

Q: Do shareholders need to submit new proxies for the reconvened meeting?

No. Existing proxies remain valid , though holders may revoke or amend them before the meeting.

Q: Which proposals still require a vote at the SunLink (SSY) special meeting?

1) Merger with Regional Health Properties ; 2) Non-binding merger-related compensation proposal .

Q: What is the record date for voting eligibility at the reconvened meeting?

The record date remains 20 Jun 2025 .

Q: Where can investors access the joint proxy statement/prospectus for the proposed SSY merger?

It is available free on the SEC website , SunLink's investor page, and Regional Health Properties鈥� investor page.

[Form 4] PLAYSTUDIOS, Inc. Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

On 29 Jul 2025 SunLink Health Systems (SSY) filed an 8-K disclosing the outcome of its special shareholder meeting regarding the proposed merger with Regional Health Properties. Only the adjournment proposal was voted; it passed with 3,205,684 For, 863,979 Against, 911 Abstentions. Consequently, the meeting was adjourned and will reconvene on 4 Aug 2025 at 10:00 a.m. ET at the Hyatt House Hotel in Atlanta.

The record date remains 20 Jun 2025 and all previously submitted proxies stay valid, though investors may revoke or amend them. No votes were taken on the merger itself or the non-binding compensation proposal, so shareholder approval for the SunLink-Regional combination is still pending. SunLink furnished a related press release (Exhibit 99.1) and included customary forward-looking-statement and solicitation disclaimers.

Positive

Adjournment approved, allowing management additional time to secure votes for the Regional Health Properties merger.
Proxies remain valid, reducing administrative burden for shareholders and management.

Negative

Need for adjournment suggests insufficient current support for the merger, introducing uncertainty and potential delay.
No merger vote yet, leaving the strategic combination鈥攁nd its expected synergies鈥攗nresolved.

Insights

TL;DR: Adjournment approved; merger decision delayed, neutral impact.

Shareholders agreed to adjourn, signalling neither clear support nor rejection of the Regional merger. The additional week gives management time to solicit votes, but also highlights that current support may be insufficient. With no financial metrics disclosed, the filing is procedurally important yet not immediately value-changing. I view the event as neutral until final merger votes are tallied.

TL;DR: Procedural step keeps deal alive; timing risk rises.

Approval of the adjournment preserves the transaction timeline, avoiding an outright failure. However, the need for adjournment indicates potential vote scarcity, introducing execution risk. Investors should monitor vote-solicitation efforts and any concessions offered before 4 Aug. Until final terms are approved, deal certainty remains below 100%.

07/29/2025 - 04:59 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

ZANELLA STEVEN J

(Last)

(First)

(Middle)

10150 COVINGTON CROSS DRIVE

(Street)

LAS VEGAS

89144

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
PLAYSTUDIOS, Inc. [ MYPS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	07/28/2025		A⁽¹⁾		120,000⁽²⁾	A⁽¹⁾	$0	244,992⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Grant of Restricted Stock Units. Each Restricted Stock Unit represents the contingent right to receive, upon vesting and settlement, one share of Class A Common Stock.

2. Represents shares of Class A Common Stock to be issued upon vesting and settlement of Restricted Stock Units, which will vest in four (4) equal tranches on August 15, 2025, November 15, 2025, February 15, 2026 and May 15, 2026, subject to continued service as a member of the Board of Directors of the Issuer.

3. Includes shares of Class A Common Stock to be issued upon vesting and settlement of Restricted Stock Units reported on this Form 4.

Remarks:

	/s/ Joel Agena, Attorney-in-Fact	07/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

When will SunLink's reconvened special meeting take place?

4 Aug 2025 at 10:00 a.m. ET at Hyatt House Hotel, 3595 Cumberland Blvd., Atlanta.

What were the vote totals for the adjournment proposal at SSY's special meeting?

For: 3,205,684; Against: 863,979; Abstentions: 911; no broker non-votes.

Do shareholders need to submit new proxies for the reconvened meeting?

No. Existing proxies remain valid, though holders may revoke or amend them before the meeting.

Which proposals still require a vote at the SunLink (SSY) special meeting?

1) Merger with Regional Health Properties; 2) Non-binding merger-related compensation proposal.

What is the record date for voting eligibility at the reconvened meeting?

The record date remains 20 Jun 2025.

Where can investors access the joint proxy statement/prospectus for the proposed SSY merger?

It is available free on the SEC website, SunLink's investor page, and Regional Health Properties鈥� investor page.

AG真人官方

[Form 4] PLAYSTUDIOS, Inc. Insider Trading Activity

Insights

FAQ

When will SunLink's reconvened special meeting take place?

What were the vote totals for the adjournment proposal at SSY's special meeting?

Do shareholders need to submit new proxies for the reconvened meeting?

Which proposals still require a vote at the SunLink (SSY) special meeting?

What is the record date for voting eligibility at the reconvened meeting?

Where can investors access the joint proxy statement/prospectus for the proposed SSY merger?

NASDAQ:MYPS

MYPS Rankings

MYPS Latest News

MYPS Latest SEC Filings

MYPS Stock Data

AG真人官方

Trending News

[Form 4] PLAYSTUDIOS, Inc. Insider Trading Activity

Insights

Financial Analyst neutral

M&A Specialist neutral

FAQ

When will SunLink's reconvened special meeting take place?

What were the vote totals for the adjournment proposal at SSY's special meeting?

Do shareholders need to submit new proxies for the reconvened meeting?

Which proposals still require a vote at the SunLink (SSY) special meeting?

What is the record date for voting eligibility at the reconvened meeting?

Where can investors access the joint proxy statement/prospectus for the proposed SSY merger?

NASDAQ:MYPS

MYPS Rankings

MYPS Latest News

MYPS Latest SEC Filings

MYPS Stock Data